Welcome to our dedicated page for Abbvie news (Ticker: ABBV), a resource for investors and traders seeking the latest updates and insights on Abbvie stock.
AbbVie Inc. reports pharmaceutical developments across immunology, neuroscience, oncology and Allergan Aesthetics. Recurring updates include financial results by product portfolio, clinical and real-world data for therapies such as SKYRIZI and RINVOQ, FDA regulatory submissions and response letters, and medical-conference presentations in inflammatory bowel disease and other immune-mediated conditions.
Company news also covers pipeline spending, acquired in-process research and development, manufacturing capacity for medicines in core therapeutic areas, and investor conference appearances. AbbVie’s product references commonly include SKYRIZI, RINVOQ, Botox Therapeutic, Vraylar, Ubrelvy, Qulipta, Venclexta, Imbruvica and Elahere.
Allergan Aesthetics (NYSE:ABBV) presented four e-posters at AAD on March 30, 2026, reporting Phase 3 and real-world aesthetics findings.
Key TrenibotE results: investigational serotype E showed rapid onset (as early as 8 hours), shorter duration (2–3 weeks), consistent efficacy across three repeat open-label treatments, a consistent safety profile, and no neutralizing antibody development.
GLP-1 patient insights: 52% expressed facial concerns; 32% were new to practices; top barriers were cost (82%) and fear of unnatural results (58%).
AbbVie (NYSE: ABBV) will present 24 abstracts at the 2026 AAD Annual Meeting (March 27–31), highlighting clinical and real-world evidence across dermatology. Key data include 5-year risankizumab radiographic nonprogression (88% no progression), up to 6-year upadacitinib safety covering >9,000 patient-years, and Phase 3 vitiligo and alopecia areata results.
Findings emphasize sustained efficacy, long-term safety across age groups, quality-of-life gains (DLQI 0/1 up to 88.9%), and a late-breaking upadacitinib vitiligo abstract; supplemental FDA labeling for risankizumab in genital and scalp psoriasis was also noted.
Allergan Aesthetics (ABBV) will present 21 evidence-based e-posters at AMWC Monaco, March 26-28, 2026, covering clinical, real-world and preclinical research. Key highlights include investigational neurotoxin trenibotulinumtoxinE with rapid improvement as early as 8 hours and short 2-3 week duration, BOTOX Cosmetic real-world satisfaction and multimodal care trends, VYC-12L/VYC-20L hyaluronic acid data with up to 6 months of benefit, HA-CaHA durability to 18 months, and CoolSculpting molecular evidence for lasting fat reduction.
Allergan Aesthetics (NYSE:ABBV) introduced the concept of an "Undetectable† Era" for hyaluronic acid (HA) injectables at AMWC Monaco on March 26, 2026. Research of 12,000 consumers in nine countries found strong demand for subtle, natural-looking results and personalized treatment plans.
JUVÉDERM® is presented as a versatile HA portfolio supporting individualized, long-lasting, reversible outcomes and practitioner-led multimodal approaches such as AA Signature™ and MD Codes™ training.
AbbVie (NYSE: ABBV) announced a multi-year partnership with Major League Baseball beginning in the 2026 season to expand Striking Out Cancer league-wide. AbbVie will donate $20 per strikeout up to $1 million per season, with proceeds benefiting Stand Up To Cancer. The program launches March 25, 2026, and includes enhanced activations around marquee events and AbbVie presenting the 2026 Wild Card Series.
NImmune Biopharma will present preclinical and translational data on LANCL2-targeting therapeutics at IMMUNOLOGY2026 (April 15–19, 2026). Data show oral NIM-1324 and topical omilancor outperforming current psoriasis treatments in multiple mouse models, first-in-human NIM-1324 met primary and secondary endpoints, and NIM-1324 is Phase 2-ready for ulcerative colitis and other indications.
Findings highlight LANCL2-driven Treg enhancement, reduced pro-inflammatory mediators, improved phagocyte clearance, and translational blood signatures supporting target engagement.
Allergan Aesthetics (NYSE: ABBV) unveiled global consumer research from more than 12,000 respondents and is presenting an evolution of its AA Signature™ multimodal framework at AMWC 2026 in Monaco. Key findings: 62% find multiple treatments appealing, 59% favor structured multi-treatment plans, and 78% prefer long-term agreed plans. The company also highlighted that 74% intend to improve skin quality in the next 12 months and introduced AA Signature™ Skin360+ to integrate injectables with energy-based devices.
The program includes symposia, live injection sessions, a Global Medical Affairs symposium, and 21 scientific e-posters to support practitioner education and multimodal treatment planning.
AbbVie (NYSE: ABBV) announced positive topline Phase 1 multiple ascending dose results for ABBV-295 on March 9, 2026. ABBV-295, a long-acting amylin analog, produced dose-dependent mean weight reductions of -7.75% to -9.79% at week 12 (weekly dosing) and -7.86% to -9.73% at week 13 (alternate dosing), versus placebo ~-0.25%.
The study tested 2–14 mg doses, enrolled mostly male participants (88.3%), showed a favorable tolerability profile with no serious adverse events, and reported mostly mild gastrointestinal events early in treatment. Full data will be presented at a future scientific conference.
Allergan Aesthetics (NYSE:ABBV) released data on March 4, 2026 showing Medical Weight Loss (MWL) is reshaping aesthetic demand, with patients prioritizing facial appearance and volume restoration.
Key metrics: 67% changed goals toward appearance, 61% report midface volume loss, 81% of HCPs favor HA fillers, and 60% of GLP-1 users obtain medications from providers who also offer aesthetic services (up from 49%).
AbbVie (NYSE: ABBV) will participate in the Leerink Partners Global Healthcare Conference on Tuesday, March 10, 2026. Management will take part in a fireside chat at 10:20 a.m. Central Time. A live audio webcast will be available via AbbVie's Investor Relations site, with an archived edition posted later that day.